Expression of epidermal growth factor receptor (EGFR) in cholangiocarcinomas: predictive factors and survival

Gomes, Rodrigo Vieira; Rodrigues, Michele Ângela; Rodrigues, João Bernardo Sancio Rocha; Vidigal, P.T.; Damasceno, Karine Araújo; Lima, Henrique A.; Gomes, Dawidson Assis; Machado, Carla Jorge; Resende, Vívian

doi:10.1590/0100-6991e-20181826

Cited by 9 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This review included 15 different studies which report Epidermal Growth Factor Receptor (EGFR) presence in CCA [ 50 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 ]. Ten out of fifteen studies investigating EGFR involve Eastern tissue specimens from Japan, China, Korea, and Thailand with 5/15 originating from USA, Brazil, Italy, and Germany.…”

Section: Resultsmentioning

confidence: 99%

Translating Biomarkers of Cholangiocarcinoma for Theranosis: A Systematic Review

Wijetunga

McVeigh

Charalambous

et al. 2020

Cancers

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA) is a rare disease with poor outcomes and limited research efforts into novel treatment options. A systematic review of CCA biomarkers was undertaken to identify promising biomarkers that may be used for theranosis (therapy and diagnosis). MEDLINE/EMBASE databases (1996–2019) were systematically searched using two strategies to identify biomarker studies of CCA. The PANTHER Go-Slim classification system and STRING network version 11.0 were used to interrogate the identified biomarkers. The TArget Selection Criteria for Theranosis (TASC-T) score was used to rank identified proteins as potential targetable biomarkers for theranosis. The following proteins scored the highest, CA9, CLDN18, TNC, MMP9, and EGFR, and they were evaluated in detail. None of these biomarkers had high sensitivity or specificity for CCA but have potential for theranosis. This review is unique in that it describes the process of selecting suitable markers for theranosis, which is also applicable to other diseases. This has highlighted existing validated markers of CCA that can be used for active tumor targeting for the future development of targeted theranostic delivery systems. It also emphasizes the relevance of bioinformatics in aiding the search for validated biomarkers that could be repurposed for theranosis.

show abstract

Section: Resultsmentioning

confidence: 99%

Translating Biomarkers of Cholangiocarcinoma for Theranosis: A Systematic Review

Wijetunga

McVeigh

Charalambous

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…According to data from the José Alencar Gomes da Silva National Cancer Institute (INCA) on breast cancer, 73,610 new cases were predicted in Brazil for the years 2023 to 2025, representing 30.1% of cancer cases, except for melanoma among women. Furthermore, for the state of Amazonas, it was estimated that there will be 500 new cases of breast cancer, of which 84% are predicted for the capital 1 Breast cancer is a disease with diverse clinical and histopathological presentations, and therefore, it has treatments, procedures and prognoses that are directly influenced by immunohistochemistry (IHC) markers such as estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and Ki67 (a proliferation index), along with assessment of tumor size, tumor grade and nodal status 2 .…”

Section: Introductionmentioning

confidence: 99%

“…However, attention should be paid to the HER2 subtype, which tends to grow and spread faster than the other subtypes, in addition to having the second worst prognosis, behind only the triple negative subtype. However, through target-specific therapy, a marked improvement in the prognosis of these patients is observed 2 .…”

Section: Introductionmentioning

confidence: 99%

Five-year retrospective study of HER2+ breast cancer in a referral hospital in the state of Amazonas

Silva,

Pereira,

Moraes

et al. 2023

Mastology

View full text Add to dashboard Cite

Introduction: Breast carcinoma is considered the most common malignancy in women, with a high incidence in Brazil and in the North region, surpassed only by non-melanoma skin cancer and cervical cancer. The HER2+ molecular subtype tends to grow and spread more quickly than other subtypes, resulting in the second worst outcome, behind only the triple-negative subtype. Methods: This was a retrospective, descriptive epidemiological study, using data from the medical records of 192 patients with HER2+ breast cancer treated at the Fundação Centro de Controle de Oncologia do Amazonas (FCECON), from 2014 to 2018. Results: The mean age of patients was 52±12 years. The predominant origin was Manaus. AM (53.1%). The most common education level was complete secondary education (36.5%) and the occupation was self-employed (37%). Most diagnoses were made in 2014 (23.4%). Regarding staging, the most common ones were stages IIIA and IIIB, both 20.83%. Concerning treatment, all patients (100%) underwent radiotherapy and chemotherapy, and surgery in 80.2%, including mastectomy (58.33%) and quadrantectomy (21.87%). Local recurrence and distant metastasis were both found in 7.3% of patients. With respect to the outcome, patients in follow-up predominated (53.6%), while mortality rate was 0.5%. Conclusions: The series demonstrated that patients with HER2 breast cancer present advanced staging and undergo neoadjuvant chemotherapy and surgery. The center in the present study is an institution that receives patients from several municipalities in the countryside of Amazonas and other states, and thus, many patients with advanced stages are cared for, since many such cities have no resources to perform mammography, compromising screening.

show abstract

Development of CAR-T Therapies and Personalized Vaccines for the Treatment of Cholangiocarcinoma: Current Progress, Mechanisms of Action, and Challenges

Li,

Andaloori,

Crowe

et al. 2024

The American Journal of Pathology

View full text Add to dashboard Cite

Expression of epidermal growth factor receptor (EGFR) in cholangiocarcinomas: predictive factors and survival

Abstract: EGFR expression occurred in 28.6% of the cases studied and was associated with lower survival.

Cited by 9 publications

References 26 publications

Translating Biomarkers of Cholangiocarcinoma for Theranosis: A Systematic Review

Translating Biomarkers of Cholangiocarcinoma for Theranosis: A Systematic Review

Five-year retrospective study of HER2+ breast cancer in a referral hospital in the state of Amazonas

Development of CAR-T Therapies and Personalized Vaccines for the Treatment of Cholangiocarcinoma: Current Progress, Mechanisms of Action, and Challenges

Contact Info

Product

Resources

About